Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Revitalize Energy, Inc.
WARNING LETTER
•Revitalize Energy, Inc.•April 14, 2025

Revitalize Energy, Inc. – FDA Warning Letter, Apr 14, 2025

Record Details

**FDA Warning Letter Summary**

**Company Name:** Revitalize Energy

**Inspection Date:** April 14, 2025

**Main Violations/Issues:** The FDA identified significant regulatory violations concerning the marketing of Revitalize Energizing Eye Drops. The product is classified as an unapproved new drug under sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), as it is introduced into interstate commerce without FDA approval. Additionally, the product is misbranded under section 502(ee) of the FD&C Act. The eye drops are marketed with claims that suggest they are intended to diagnose, cure, mitigate, treat, or prevent disease, which necessitates FDA approval. The product"s labeling and promotional materials on the company"s website and social media platforms make claims about relieving eye strain, boosting focus, and refreshing tired eyes, which further support its classification as a drug.

**Regulatory Framework:** The product is subject to the FD&C Act, specifically sections 505(a), 301(d), and 502(ee), which govern the approval and marketing of drug products. The eye drops do not conform to the applicable Over-the-Counter (OTC) monograph M018 for ophthalmic drug products, as they contain active ingredients like menthol, camphor, caffeine, and taurine, which are not permitted under the monograph.

**Required Actions:** Revitalize Energy must cease the introduction of the unapproved and misbranded product into interstate commerce. The company is required to obtain FDA approval for the product or modify its formulation and labeling to comply with applicable OTC monograph standards. Immediate corrective actions are necessary to address these violations, and the company must respond to the FDA with a plan to rectify the issues.

Company
Revitalize Energy, Inc.
Inspection date
April 14, 2025
Product type
Drugs
Office
Center for Drug Evaluation and Research
Person
  • Tina Smith (Director)
View Company Profile

ID · 018152b7-c36d-4992-9ea3-a6767cf378f0

Violation Codes10
FD&C Act 505(a)FD&C Act 301(d)21.U.S.C. 355(a)21 U.S.C. 331(d)FD&C Act 502(ee)21 U.S.C. 352(ee)FD&C Act 301(a)FD&C Act 201(g)(1)(B)21 U.S.C. 321(g)(1)(B)FD&C Act 201(g)(1)(C)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Revitalize Energy, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.